DNTH - CIK 0001690585
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported net income of -$162.34M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$162.34M | -91.1% |
| FY 2024 | -$84.97M | -95.1% |
| FY 2023 | -$43.55M | -52.9% |
| FY 2022 | -$28.48M | -117.2% |
| FY 2021 | -$13.11M | +82.5% |
| FY 2020 | -$74.94M | +2.4% |
| FY 2019 | -$76.77M | -33.5% |
| FY 2018 | -$57.52M | -62.1% |
| FY 2017 |
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported net income of -$162.34M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Dianthus Therapeutics, Inc. /DE/'s net income declined from -$9.43M to -$162.34M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$35.49M |
| -276.3% |
| FY 2016 | -$9.43M | - |